Anavex announces new findings for blarcamesine

Anavex (AVXL) Life Sciences announced new findings for blarcamesine, an oral small molecule for the potential treatment of early Alzheimer’s disease. New data demonstrate continued long-term benefit from oral blarcamesine compared to decline observed in the Alzheimer’s Disease Neuroimaging Initiative control group. Externally matched control participants from the ADNI database were compared with participants over the 144-week period of ANAVEX2-73-AD-004 and its ATTENTION-AD open-label extension Phase IIb/III trial.2 For ADAS-Cog13, total score ranges from 0 to 85 with higher scores indicating increased cognitive impairment. In the Phase IIb/III oral blarcamesine early Alzheimer’s disease trial, oral blarcamesine resulted in 77.4 weeks of time saved in the ITT population compared to the ADNI control group. This measure provides a meaningful clinical perspective, emphasizing the real-world impact of treatment on patients’ daily lives and highlighting the potential for long-term therapeutic benefit. The clinical trial data on blarcamesine also confirmed the upstream mechanism of blarcamesine, restoring impaired autophagy as an early event, preceding amyloid-beta and tau. Anavex plans to publish and present this new data at international Alzheimer’s disease conferences.